Pharmacology

• 206Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments. J Am Heart Assoc.2023
  doi: 10.1161/JAHA.122.028146. PubMed
• 205Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients. Int Urol Nephrol.2023
  doi: 10.1007/s11255-023-03532-1. PubMed
• 182 Tubular Injury Causing Protracted GlycosuriaFollowing Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in theDevelopment of Protracted Hypoglycemia and Ketoacidosis. Tohoku J ExpMed.2021
  doi: 10.1620/tjem.255.291. PubMed
• 179Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition onBiomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized ControlledTrial. J Diabetes Res.2021
  doi: 10.1155/2021/7382620.PubMed
• 138Effect of linagliptin on oxidative stress markers in patientswith type 2 diabetes: a pilot study.Diabetol Int.2018PubMed
• 136Effect of canagliflozin, a sodium glucose co-transporter 2inhibitor, on cisplatin-induced nephrotoxicity in mice.NaunynSchmiedebergs Arch Pharmacol.2018PubMed
• 129Anagliptin ameliorates albuminuria and urinary liver-type fattyacid-binding protein excretion in patients with type 2 diabetes with nephropathy in aglucoselowering-independent manner.BMJ Open Diabetes Res Care.2017PubMed
• 126Role of bardoxolone methyl, a nuclear factor erythroid 2-relatedfactor 2 activator, in aldosterone- and salt-induced renal injury. Hypertens Res.2017PubMed
• 125Renoprotective effect of the xanthine oxidoreductase inhibitorTopiroxostat under decreased angiotensin II type 1a receptor expression.Eur J Pharmacol. 2017PubMed
• 115The protective effect of human atrial natriuretic peptide onrenal damage during cardiac surgery.J Anesth.2016PubMed
• 113The association between urinary liver-type fatty acid-bindingprotein and chronic kidney disease classification in HIV-infected Japanese patients. Clin Exp Nephrol.2016PubMed
• 107Impact of teneligliptin on oxidative stress and endothelialfunction in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc Diabetol.15(1): 76, 2016.PubMed
• 106Renoprotective effect of the xanthine oxidoreductase inhibitor,Topiroxostat,on Adenine-Induced Renal Injury.Am J Physiol RenalPhysiol.310(11):F1366-1376, 2016.PubMed
• 96Epoetin beta pegol alleviates oxidative stress and exacerbationof renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritisrats.Physiol Rep.3(12), 2015.PubMed
• 91Urinary ACE2 is associated with urinary L-FABP and albuminuria inpatients with chronic kidney disease.Scand J Clin LabInvest.75(5): 421-427, 2015.PubMed
• 89Does elevation of serum creatinine in patients with chronichepatitis C under therapy of telaprevir mean renal impairment? Nephrology.10(4):e0122212, 2015.PubMed
• 85Renoprotective effects of febuxostat in hyperuricemic patientswith chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol.19(6): 1044-1053, 2015.PubMed
• 62A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reducesrenal tubulointerstitial fibrosis by suppressing PAI-1.Am J Physiol RenalPhysiol.305(12): F1796-1803, 2013.PubMed
• 58Spironolactone diminishes urinary albumin excretion in patientswith type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med.29(8): e184-190, 2012.PubMed
• 56Renoprotective and antioxidant effects of cilnidipine inhypertensive patients.Hypertens Res.35(11): 1058-1062, 2012.PubMed
• 51Potential Benefit of Statin Therapy for Dyslipidemia with ChronicKidney Disease: Fluvastatin Renal Evaluation Trial (FRET).InternalMedicine.50(12): 1273-1278, 2011.PubMed
• 50Additive antioxidative effects of azelnidipine on angiotensinreceptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res .34: 935-941, 2011.PubMed
• 39Comparative effects of benidipine and amlodipine on proteinuria,urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidneydisease.Am J Med Sci.339(2): 157-163, 2010.PubMed
• 38Renoprotective Effects of Various Angiotensin II ReceptorBlockers in Patients with Early-Stage Diabetic Nephropathy.Kidney BloodPress Res.33(3): 213-220, 2010.PubMed
• 37Effects of telmisartan and enalapril on renoprotection inpatients with mild to moderate chronic kidney disease.Eur J ClinInvest.40(9): 790-796, 2010.PubMed
• 35Urinary L-type fatty acid-binding protein can reflect renaltubulointerstitial injury.Am J Pathol.174(4): 1203-1211, 2009.PubMed
• 33Tubular and glomerular injury in diabetes and the impact of ACEinhibition.Diabetes Care.32(9): 1684-1688, 2009.PubMed
• 26Renal L-type fatty acid-binding protein mediates the bezafibratereduction of cisplatin-induced acute kidney injury.KidneyInt.73(12): 1374-1384, 2008.PubMed
• 25Renoprotective effect of telmisartan in patients with chronickidney disease.Clin Exp Hypertens.30(7): 662-672, 2008.PubMed
• 24Additional renoprotective effects of azelnidipine combined withangiotensin receptor blockers in patients with diabetic nephropathy.ClinNephrol.70(5): 385-392, 2008.PubMed
• 21Angiotensin II receptor antagonist reduces urinary liver-typefatty acid-binding protein levels in patients with diabetic nephropathy and chronic renalfailure.Diabetologia.50(2): 490-492, 2007.PubMed
• 20Azelnidipine reduces urinary protein excretion and urinaryliver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci.333(6): 321-326, 2007.PubMed
• 19Beneficial effects of olmesartan and temocapril on urinaryliver-type fatty acid-binding protein levels in normotensive patients with immunoglobin Anephropathy.Am J Hypertens.20(11): 1195-1201, 2007.PubMed
• 15Urinary liver-type fatty acid-binding protein levels fordifferential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effectof low-density lipoprotein apheresis.Clin Nephrol.65(1): 1-6,2006.PubMed
• 14Effect of pioglitazone on urinary liver-type fatty acid-bindingprotein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev.22(5): 385-389, 2006.PubMed
• 13Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-BindingProtein in Patients with Chronic Renal Failure and Anemia.Am JNephrol.26(3): 276-280, 2006.PubMed
• 12Effect of pitavastatin on urinary liver-type fatty-acid-bindingprotein in patients with nondiabetic mild chronic kidney disease.Am JNephrol.26(1): 82-86, 2006.PubMed
• 7Candesartan reduces urinary fatty acid-binding protein excretionin patients with autosomal dominant polycystic kidney disease.TAm J MedSci.330(4): 161-165, 2005.PubMed
• 6Effect of Pitavastatin on Urinary Liver-Type Fatty Acid?BindingProtein Levels in Patients With Early Diabetic Nephropathy.DiabetesCare.28(11): 2728-2732, 2005.PubMed

Category

Acute Kidney Injury (AKI)　Chronic Kidney Disease (CKD)　Toxicology
Pharmacology　Exercise　COVID-19